Development
AbbVie Inc.
ABBV
$191.08
-$1.34-0.70%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 4.86B | 6.51B | 8.69B | 7.59B | 11.84B |
| Total Depreciation and Amortization | 8.70B | 8.78B | 8.75B | 8.54B | 8.47B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.47B | 7.01B | 6.04B | 7.75B | 4.73B |
| Change in Net Operating Assets | 2.81B | 3.22B | 2.07B | 356.00M | -94.00M |
| Cash from Operations | 22.84B | 25.51B | 25.54B | 24.23B | 24.94B |
| Capital Expenditure | -777.00M | -785.00M | -743.00M | -708.00M | -695.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.22B | -970.00M | -913.00M | -962.00M | -794.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.00M | 98.00M | 1.65B | 2.14B | 866.00M |
| Cash from Investing | -2.01B | -1.66B | -2.00M | 469.00M | -623.00M |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 2.00B |
| Total Debt Repaid | -4.15B | -9.21B | -11.91B | -10.91B | -14.43B |
| Issuance of Common Stock | 180.00M | 202.00M | 177.00M | 199.00M | 262.00M |
| Repurchase of Common Stock | -1.97B | -1.97B | -1.97B | -1.97B | -1.49B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -10.54B | -10.42B | -10.30B | -10.18B | -10.04B |
| Other Financing Activities | -742.00M | -1.01B | -1.27B | -1.17B | -1.10B |
| Cash from Financing | -17.22B | -22.41B | -25.26B | -24.02B | -24.80B |
| Foreign Exchange rate Adjustments | 5.00M | 5.00M | -38.00M | -61.00M | -62.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.61B | 1.46B | 238.00M | 613.00M | -545.00M |